Eris Lifesciences Receives ANVISA Approval for Sterile Injectable Facility, Achieving Comprehensive Coverage of Latin American Pharma Market

Eris Lifesciences Limited, a leading Indian branded formulations company, announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from Anvisa, Brazil's national health regulatory agency. The approval follows a successful inspection conducted by the regulatory agency in April 2025 of both the injectable facilities of Swiss Parenterals, a subsidiary acquired by Eris in 2024. The approval enables the company to launch its products in Brazil and achieve comprehensive coverage of the Latin American pharma market. Eris has built a diversified presence across specialties and super-specialties and manufactures a wide range of prescription products across several dosage forms.